Clinical Trial Update: Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NBI-5788, an altered peptide ligand, in relapsing multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• NBI-5788

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED